STUDIO CITY, Calif., March 01, 2025 (GLOBE NEWSWIRE) -- Myeloma Action Month is an annual global awareness campaign that ...

This review summarizes the mechanisms of action and clinical activity of IMiDs in MM. Multiple myeloma (MM) is a malignant plasma cell disorder accounting for approximately 10% of all hematologic ...

Multiple myeloma is a type of blood cancer that forms in plasma cells, white blood cells that produce infection-fighting antibodies. Multiple myeloma is not hereditary, meaning it is not passed ...

Survival of patients with multiple ... HRMM in clinical trials, it enables better comparability of therapeutic outcomes and guides the development of targeted interventions for this high-risk group.* ...

Here Dr. Usmani discusses the current outlook for the disease and his vision for developing new treatment approaches at MSK that will improve multiple myeloma prognosis (outcome). This includes very ...

Take strides toward a cure for multiple myeloma. Your participation supports critical research initiatives like the Black Swan Research Initiative®, propelling us closer to groundbreaking treatments ...

March 01, 2025 (GLOBE NEWSWIRE) -- Myeloma Action Month is an annual global awareness campaign that takes place every March to raise awareness and inspire action for multiple myeloma—a blood ...

A team of University of Adelaide researchers is hoping to create a world-first treatment for nerve damage caused by ...

Possible risks of participating in a lung cancer clinical trial Since it's always better to get the big picture before making any decisions, here's a list of some of the possible risks of ...